Department of Surgery

Welcome to the Department of Surgery (2)
We are Specialists in Cardiovascular,
Breast/Endocrine, and Thoracic Surgery.

HOME > Academic Activities > Conference Presentations

Academic Activities

Breast and Endocrine Surgery

  • 【2017】
  • American Association for Cancer Research Annual Meeting 2017 (Washington D.C. 2017/4/1)
    1) Iesato A, Nakamura T, Izumi H, Uehara T, Ito K
    PATZ1 promotes migration and invasion of thyroid cancer cells through upregulation of the activity of plasminogen activator and matrix metalloproteinases.
    2) Oba T, Ito K
    Preclinical analyses of synergistic effect of eribulin and paclitaxel for triple-negative breast cancer.
    3) Tominaga Y, Ito K, Nakayama J
    Decreased expression of 5-hydroxymethylcytosine is associated with grade of malignancy in lung cancer.
  • San Antonio Breast Cancer Symposium 2017 (San Antonio 2017/12/5-9)
    Maeno K, Yamamoto K, Ono M, Oba T, Iesato A, Koichi Ono, Ito T, Kanai T, Ito K
    A feasibility study of sentinel lymph node detection and analysis of safety to omit axillary lymph node dissection in clinically node-negative breast cancer patients after neoadjuvant chemotherapy.
  • Sorafenib DTC Medical Symposium (Seul 2017/12/9)
    Ito K
    Insights of TKI use for thyroid cancer in Japan.
  • 【2016】
  • 27th Annual Meeting of Asia-Pacific Endocrine Conference(Hawaii 2/12)
    Ito K, Ono M, Oba T, Iesato A, Fukushima Y, Ito T, Nakajima H, Kanai T, Maeno K.
    Vandetanib in Patients with Unresectable or Metastasic Medullary Thyroid Cancer.
  • 13th international congress of human genetics(Kyoto 4/3-7)
    Iesato A, Ono M, Oba T, Fukushima Y, Ito T, Kanai T, Maeno K, Ito K, Kise E, Ishikawa M, Yamashita H, Takano K, Kosho T, Fukushima Y, Miyamoto T, Takatsu A, Shiozawa T
    Trend analysis of the cases who received genetic counseling for HBOC in Shinshu Univ. Hosp.
  • AACR Annual meeting 2016(New Orleans 4/16-20)
    Oba T, Izumi H, Taniguchi S, Ito K
    ABCC11/MRP8 and ABCB1/MDR1 confer eribulin resistance to breast cancer cells.
  • 【2015】
  • -
  • 【2014】
  • -
  • 【2013】
  • AACR Annual meeting 2013 (Washington DC 2013/ 4/6-10
    1) Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C, Kobayashi Y, Kurosumi M, Takei H,Yamaguchi Y, Ito K, Hayashi S
    The androgen metabolite-dependent growth of hormone receptor positive breast cancer as a possible aromatase inhibitor-resistance mechanism
    2) Okada T, Ito K, Amano J, Onoda N
    Association of CD44 expression and ALDH1 activity in thyroid cancer

    2nd World Congress on Thyroid Cancer (Toronto 2013/7/10-14)
    Maeno K, Iesato A, Okada T, Hanamura T, Watanabe T, Kanai T, Ito K, Amano J
    Clinical significance of poorly differentiated component in the differentiated thyroid carcinoma

    San Antonio Breast Cancer Symposium 2013 (San Antonio 2013/12/11-13)
    Watanabe T, Okada T, Oba T, Iesato A, Hanamura T, Kanai T, Maeno K, Ito K
    Alteration of sensitivity to chemotherapeutic agents in tamoxifen resistant estrogen receptor positive breast cancer
  • 【2012】
  • 13th Asian Association of Endocrine Surgeons Congress 2012 (Singapore 2012/3/26-28)
    1) Koyama H, Murayama K, Muramatsu S, Okada T, Watanbe T, Maeno K, Mochizuki Y, Ito K, Amano J
    A retrospective Analysis of the patients of Parapharyngeal Lymph Node Metastasis from Thyroid Cancer.
    2) Kudo M, Murayama K, Okada T, Watanabe T, Koyama H, Maeno K, Mochizuki Y, Ito K, Amamo J
    A retrospective analysis of patients with medullary thyroid carcinoma.

    San Antonio Breast Cancer Symposium 2012 (San Antonio, USA 12/4-8)
    Hanamura T, Niwa T, Nishikawa S, Konno H, Ghono T, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K, Hayashi S
    The androgen metabolite-dependent growth in hormone receptor positive breast cancer as a novel aromatase inhibitor-resistance mechanism
  • 【2011】
  • San Antonio Breast Cancer Symposium 2011 (San Antonio, USA, 2011/12/6)
    Ito T, Kamijyo S, Izumi H, Kohno K, Amano J, Ito K
    Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor positive breast cancer
  • 【2010】
  • 2th Congress of the Asian Association of Endocrine Surgeons (Tokyo, 2010/3/23)
    Ito K, Okada T, Ito T, Watanabe T, Kanai T, Maeno K, Mochizuki Y, Amano J
    Multimodality therapeutic approach in anaplastic thyroid carcinoma
  • 【2009】
  • orld congress on thyroid cancer (Toronto, Canada, Sheraton Centre Toronto Hotel, 2009/8/7)
    Ito K, Hanamura T, Murayama K, Ito T, Kanai T, Maeno K, Mochizuki Y, Amano J
    A multimodality therapeutic approach in anaplastic thyroid carcinoma: Study on 37patients
  • 【2008】
  • Advanced in Neuroblastoma Research 2008 (Chiba, JAPAN, Makuhari Messe, 2008/5/22)
    Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR,London WB, Maris JM, White PS, Brodeur GM
    CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.

    Second JCA-AACR Special Joint Conference (Hyogo, Japan, 2008/7/14)
    1) Komatsu A, Nagasaki K, Fujimori M, Amano J, Miki Y
    Identification of novel deletion polymorphisms in breast cancer
    2) Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K,Tsuchiya S, Kohno K, Fujimori M, Amano J
    Increased Nuclear Localization of Transcription Factor Y-Box Binding Protein 1 Accompanied by Up-regulation of P-glycoprotein in Breast Cancer Pretreated with Paclitaxel

    5th Annual North American ABC Genetic Workshop (Frederick, National Cancer Institute, U.S.A., 2008/9/24)
    Maeno K, Nakajima A, Conseil G, Rothnie A, Deeley RG, Cole SPC
    Analysis of S-MethylGSH Stimulated Estrone Sulfate Transport and Modulator Sensitivity of TM6 and TM17 Mutants of MRP1 (ABCC1)